JAMA

EQS-News: G.ST Antivirals reports start of Phase II trial and announces appointment of Ronald Bruce Turner as new Chief Medical Officer

Retrieved on: 
Wednesday, April 10, 2024
JAMA, Recreational vehicle, Metabolism, CHDR, Entrepreneurship, Dean (education), Viral, Reproduction, University, Head, Volunteering, MD, Urinary tract infection, Infection, Medical school, Clinical trial, Pharmacokinetics, Southern Illinois University, Division, Virus, CMO, University School, Glycolysis, Pharmaceutical industry

An expert in the clinical research of respiratory viruses, Dr. Turner will oversee the Company’s current clinical trial and drive further clinical development.

Key Points: 
  • An expert in the clinical research of respiratory viruses, Dr. Turner will oversee the Company’s current clinical trial and drive further clinical development.
  • This study aims to assess the effectiveness of 2-DG in preventing illness from rhinoviruses, reducing infection rates, and easing symptom severity.
  • A total of 128 volunteers will participate, receiving up to four daily intranasal doses of either 2-DG or a placebo.
  • 2-DG is a unique and intriguing therapeutic approach to treating viral infections by blocking the virus’ nutrient access,” commented Ronald Bruce Turner, MD, CMO of G.ST Antivirals.

Silence Therapeutics Announces JAMA Publication of Additional Phase 1 Data for Zerlasiran in Subjects with Elevated Lipoprotein(a)

Retrieved on: 
Monday, April 8, 2024
Research, FDA, Genetics, Clinical Trials, Cardiology, Biotechnology, Health, Pharmaceutical, Science, JAMA, American Medical Association, Cardiovascular disease, Serum, Patient, Journal, RNA, MD, Therapy, Moyamoya disease, Safety, Small RNA, APOLLO, ASCVD, Pharmaceutical industry

“Positive phase 1 data published in JAMA demonstrate treatment with zerlasiran produced sustained reductions in Lp(a) concentrations with a well-tolerated profile using varying dosing regimens,” said Curtis Rambaran, MD, Chief Medical Officer at Silence and senior author of the publication.

Key Points: 
  • “Positive phase 1 data published in JAMA demonstrate treatment with zerlasiran produced sustained reductions in Lp(a) concentrations with a well-tolerated profile using varying dosing regimens,” said Curtis Rambaran, MD, Chief Medical Officer at Silence and senior author of the publication.
  • Results from the single ascending dose portion of the trial in healthy participants were previously published in the April 2022 issue of JAMA, linked here .
  • Secondary outcomes included the serum levels of zerlasiran and effects on Lp(a) serum concentrations.
  • Zerlasiran is currently being evaluated in the ALPACAR-360 phase 2 study in subjects with baseline Lp(a) levels at or over 125 nmol/L at high risk of ASCVD events.

Nathan Kuppermann, M.D., M.P.H., named chief academic officer and chair of Pediatrics at Children’s National Hospital

Retrieved on: 
Wednesday, March 13, 2024
JAMA, Research, Health care, Health, Public, Public health, EVP, UCSF School of Medicine, Pediatric Research, Education, UC, Global Health, Emergency medicine, Society, Publication, Emergency medical services, Hospital, Children's National Hospital, Stanford University, National academy, MHA, Pediatrics, BMJ

Washington, D.C., March 13, 2024 (GLOBE NEWSWIRE) -- Children's National Hospital has appointed Nathan Kuppermann, M.D., M.P.H., as its new executive vice president (EVP), chief academic officer (CAO) and chair of Pediatrics.

Key Points: 
  • Washington, D.C., March 13, 2024 (GLOBE NEWSWIRE) -- Children's National Hospital has appointed Nathan Kuppermann, M.D., M.P.H., as its new executive vice president (EVP), chief academic officer (CAO) and chair of Pediatrics.
  • He comes to Children’s National from UC Davis Health and UC Davis School of Medicine in Sacramento, CA, and will start in September.
  • After a national search, Dr. Kuppermann stood out for his exceptional contributions to clinical and academic research, focusing on pediatric emergency care, and his dedication to mentorship.
  • He completed a pediatrics residency and chief residency at Harbor-UCLA Medical Center and a fellowship in Pediatric Emergency Medicine at Boston Children's Hospital.

Fight Colorectal Cancer Unites Over 200 Advocates in Washington, D.C. for the 18th Annual Call-on Congress Event

Retrieved on: 
Tuesday, March 12, 2024
JAMA, Colorectal cancer, Congress, Disease, Caregiver, Incidence, Ageing, Exact sciences, Research, Woman, Statistics, Survivor, CDC, CRC, Large intestine, Dairy

WASHINGTON, D.C., March 12, 2024 (GLOBE NEWSWIRE) -- In a powerful display of unity, Fight Colorectal Cancer (Fight CRC) is hosting the 18th Annual Call-on Congress event, bringing together over 200 colorectal cancer survivors, caregivers, and loved ones.

Key Points: 
  • WASHINGTON, D.C., March 12, 2024 (GLOBE NEWSWIRE) -- In a powerful display of unity, Fight Colorectal Cancer (Fight CRC) is hosting the 18th Annual Call-on Congress event, bringing together over 200 colorectal cancer survivors, caregivers, and loved ones.
  • This landmark advocacy initiative aims to elevate personal stories and press for increased funding and support to combat colorectal cancer (CRC) .
  • Colorectal cancer, encompassing colon and rectal cancers, stands as the second-leading cause of cancer deaths for both men and women combined in the United States.
  • Encouraging Members of Congress to Champion Colorectal Cancer : Advocates will call on their representatives to become champions for colorectal cancer, actively working to transform the statistics surrounding the disease by joining the Colorectal Cancer Caucus.

JAMA in America: Annual Data Release Highlights Japanese-Brand Automakers’ Significant Investment in the U.S. Economy

Retrieved on: 
Wednesday, April 3, 2024
Other Manufacturing, Automotive, Engineering, Other Automotive, Automotive Manufacturing, General Automotive, Vehicle Technology, Manufacturing, JAMA, Director general, Partnership, Motorcycle, FDI, Investment, Workforce, Multimedia, Renewable energy

Japanese-brand automakers’ ongoing and steady commitment to the U.S. automotive industry helps bolster U.S. economic competitiveness.

Key Points: 
  • Japanese-brand automakers’ ongoing and steady commitment to the U.S. automotive industry helps bolster U.S. economic competitiveness.
  • Notably, Japanese-brand automakers hit a record high $61.6 billion in cumulative manufacturing investment in 2023 as they continued to expand, retool, and modernize their facilities.
  • This year’s data release also highlights how Japanese-brand automakers directly employ over 109,000 U.S workers, another increase from last year.
  • “Japanese-brand automakers are vital to the U.S. economy, investing over $61.6 billion in their 24 U.S. manufacturing facilities over the last four decades.

Research: Surgeons, Hospitals Involved in Exceptional Research Have Lower Patient Mortality Rates, Fewer Complications

Retrieved on: 
Wednesday, April 3, 2024
Software, Research, Oncology, Technology, Hospitals, Health Technology, Science, Surgery, Cardiology, Neurology, Practice Management, Health, JAMA, Evidence-based medicine, Surgeon, Urology, Environment, Physician, Impact factor, Hospital, Mortality, Patient, General surgery, Neurosurgery, Ear, Woman, Otorhinolaryngology, Male, Publication, Novant Health, Harvard Business Review, Nose, Surgical oncology, Medicare, PubMed, Elective surgery, Gastroenterology

Surgeons and hospitals who conduct the most leading-edge research achieve lower rates of patient mortality and complications than those who do not, according to findings released today by Avant-garde Health.

Key Points: 
  • Surgeons and hospitals who conduct the most leading-edge research achieve lower rates of patient mortality and complications than those who do not, according to findings released today by Avant-garde Health.
  • Patients under the care of top surgeon-researchers showed a 5% lower rate of post-discharge complications and a 5% lower rate of mortality, within 30 days post-discharge, according to the research.
  • All 4,500 physicians and 350 hospitals being honored are listed on the Research All-Stars site .
  • In addition, a significant portion of the top surgeon-researchers – 47.1% on average – served as the leading or senior authors of their research.

Breakthrough Results of NIH-Sponsored Study of Syn-One Test® as a Skin-Based Diagnostic Tool for Parkinson’s Disease and Related Disorders Published in the Journal of the American Medical Association

Retrieved on: 
Wednesday, March 20, 2024
Research, Neurology, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, Other Science, Science, JAMA, Lewy body, Diagnosis, Harvard Medical School, American Medical Association, DLB, MSA, Disease, PD, Multiple system atrophy, Alpha-synuclein, Physician, Journal, CND, MD, NIH, Synucleinopathy, Skin, Pathology, Bangladesh Technical Education Board, Medicare, PAF, Dementia, Phosphorylation, Medical imaging

The primary goal of this study was to define the positivity rate of skin biopsies to detect P-SYN deposition in clinically confirmed cases of PD, MSA, DLB, and PAF.

Key Points: 
  • The primary goal of this study was to define the positivity rate of skin biopsies to detect P-SYN deposition in clinically confirmed cases of PD, MSA, DLB, and PAF.
  • The proportion of patients with P-SYN was 92.7% in those with PD, 98.2% in those with MSA, 96.0% in those with DLB, and 100% in those with PAF.
  • Future disease-modifying therapies will require convenient, accurate, and precise diagnostic tools to reach the right patients at the right time across a wide array of communities.
  • “The publication of this important NIH-sponsored study is one big step forward with many more milestones to come.”

Cybin Receives FDA Breakthrough Therapy Designation for its Novel Psychedelic Molecule CYB003 and Announces Positive Four-Month Durability Data in Major Depressive Disorder

Retrieved on: 
Wednesday, March 13, 2024
Alternative Medicine, Mental Health, Health, FDA, Clinical Trials, Pharmaceutical, Biotechnology, JAMA, Depression, Disability, Conference, BTD, Breakthrough therapy, Massachusetts General Hospital, Inc., Psychiatry, Clinical, Grammatical mood, Appetite, MDD, Data analysis, Patient, Knowledge, Disease, Causality, Sleep, Anhedonia, DNB, DSM-IV codes, MBBS, Suicidal ideation, Behavior, Cognition, Event, Hospital, Drug development, Safety, Injury, Multimedia, Plasma protein binding, Sadness, Lancet, BMJ, Pharmaceutical industry

If approved by the FDA, CYB003 would be the first known adjunctive psychedelic-based therapeutic for the treatment of MDD.

Key Points: 
  • If approved by the FDA, CYB003 would be the first known adjunctive psychedelic-based therapeutic for the treatment of MDD.
  • The designation of CYB003 as a breakthrough therapy acknowledges the significant unmet medical need for more effective treatments of MDD and supports CYB003’s potential for significant improvements over existing therapies.
  • With the robust durability data from our Phase 2 study in hand, we are ready to move forward expeditiously.
  • (2022) Response to acute monotherapy for major depressive disorder in randomized, placebo-controlled trials submitted to the US Food and Drug Administration: individual participant data analysis.

Battling the opioid epidemic: New research shows access to opioid use disorder treatment in emergency rooms saves lives

Retrieved on: 
Tuesday, March 26, 2024
JAMA, EDS, American Medical Association, Survival, Addiction medicine, AHS, Patient, OUD, Journal, Research, Buprenorphine, Opioid use disorder, Emergency department, Drug, ED, Alameda Health System, Pharmaceutical industry

The research points to emergency rooms as critical gateways for providers to reach and treat patients with opioid use disorder.

Key Points: 
  • The research points to emergency rooms as critical gateways for providers to reach and treat patients with opioid use disorder.
  • Emergency departments are often the lowest-barrier access point for people seeking immediate health care.
  • This research shows that initiation of buprenorphine in the emergency department, combined with linkage to outpatient treatment, saves lives.
  • The Bridge Clinic at AHS is at the forefront of bringing opioid use disorder treatment to patients in Alameda County.

HiLabs Announces Closing of $39 Million Series B Financing to Advance its AI-powered Data Management Solutions for Healthcare Organizations

Retrieved on: 
Thursday, March 14, 2024
JAMA, American Medical Association, Growth, CFO, Patient, Journal, AI, Partnership, Directory

BETHESDA, Md., March 14, 2024 /PRNewswire/ -- HiLabs, a leading provider of AI-powered solutions to manage dirty data, unlocking its hidden potential for healthcare transformation, today announced a $39 million Series B financing. The round was led by Denali Growth Partners and Eight Roads Ventures, with participation from F-Prime Capital. The capital raise follows rapid customer adoption of its healthcare data ingestion, cleansing, and enrichment platform, MCheck™, and will support continued enhancement of the technology as well as recruitment of top-tier talent and expansion of its product teams.

Key Points: 
  • BETHESDA, Md., March 14, 2024 /PRNewswire/ -- HiLabs , a leading provider of AI-powered solutions to manage dirty data, unlocking its hidden potential for healthcare transformation, today announced a $39 million Series B financing.
  • Founded in 2014, HiLabs' mission is to ensure timely access to clean data for payers, providers, and patients at a time when healthcare organizations worldwide are transitioning toward data-driven decision-making.
  • HiLabs' cloud-based MCheck platform ingests, cleans, and enriches critical healthcare information, resulting in significant reduction in healthcare organizations' operational costs and improvement in patient outcomes.
  • The company's provider directory management solution is live in most US states, analyzing data of over 80% of the country's healthcare providers.